Broadening the accessibility of biologic medicines to patients around the world.
Investors Overview
Overview
Alvotech is a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary endpoint REYKJAVIK, Iceland, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and
Product revenue for the nine months of 2023 increased to $29.8 million, compared to $11.1 million for the same period in 2022 Marketing authorization was received for AVT04 in Canada and Japan, the first for a biosimilar to Stelara ® (ustekinumab) The European Medicines Agency proposed market
REYKJAVIK, ICELAND, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first nine months of 2023, after U.S.
Pr Jamte ki TM is the second biosimilar developed under th is partnership that receives market ing authorization in Ca nada. REYKJAVIK, Iceland and BOUCHERVILLE, Quebec, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and
